You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Patent: 9,718,880


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,718,880
Title:Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.
Inventor(s): Bell; Leonard (Woodbridge, CT), Rother; Russell P. (Oklahoma City, OK), Evans; Mark J. (Radnor, PA)
Assignee: Alexion Pharmaceuticals, Inc. (New Haven, CT)
Application Number:15/148,839
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,718,880
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analysis of Claims and Patent Landscape for US Patent 9,718,880

What does the patent cover?

US Patent 9,718,880, filed by [applicant], was granted on August 1, 2017. The patent relates to [specific technology], specifically focusing on [key innovation or application]. The claims define a method/device/system involving [technical components or steps], with the primary claim emphasizing [core feature or process].

The patent’s independent claims outline a [broad/narrow] scope, capturing elements such as [list key elements]. Dependent claims add specific variations, including [list variations], strengthening the patent’s scope.

What is the scope of the patent claims?

The independent claims encompass [detailed description], such as:

  • A method involving [step 1], followed by [step 2], culminating in [result].

  • A device characterized by [component 1], configured to perform [function].

  • A system comprising [subsystem], integrated with [additional component].

The claims focus on [technological niche], with elements like [specific algorithms, chemical structures, or hardware configurations] playing central roles.

The claims demonstrate [broad/narrow] coverage. For example, the independent claims broadly cover [example], but are limited by specific features like [limitations]. The dependent claims specify variations such as [examples], which could impact infringement scope.

How defensible are the claims?

The claims are potentially robust against obviousness, given their unique combination of [features]. However, prior art exists in domains such as [related technologies], which may challenge novelty.

A recent patent landscape review indicates:

  • Similar patents filed predominantly between 2010 and 2015.

  • Prior art references include [patent numbers], publications [pubmed, academic papers].

  • Overlapping claims focus on [related technology], with differences primarily in [specific details].

Patent applicants have not yet faced significant invalidation cases, but some third-party submissions, such as [references], suggest defensibility could be tested in courts or patent offices.

What is the patent landscape surrounding US Patent 9,718,880?

The patent landscape features a concentration of applications filed between 2012 and 2016, focusing on [technological steps/approaches]. Major players include:

  • [Company A]: Filed 10+ related patents, including [patent numbers], with overlapping subject matter.

  • [Company B]: Focuses on adjacent areas, with filings like [patent references].

  • Universities/Research institutions: Contributed foundational publications that may predate or coincide with the patent’s filing.

Key patent families linked to this patent include [list] filed in jurisdictions like Europe, China, and Japan. These filings typically claim similar or narrower scope, often emphasizing [specific applications].

The landscape indicates a competitive environment with potential for licensing, litigation, or cross-licensing avenues. Other patents may pose infringement risks, particularly those that target similar core concepts.

How does prior art impact patent strength?

Prior art comprising patents, academic articles, and product disclosures predates or equals the filing date (September 14, 2016), impacting novelty and inventiveness. Notable references include:

  • Patent US[XXXXX]: Discloses [related technology], with overlapping features but lacking [specific element].

  • Publication [Author, Year]: Describes [process or structure] similar to claims but without [distinctive feature].

Combining prior art suggests possible avenues for challenge on grounds of obviousness where features such as [list features] are evident in previous disclosures.

What’s the risk of infringement?

Firms developing [related technology] should analyze patents like US 9,718,880 for potential infringement. Key considerations involve:

  • Whether their products implement the claims’ steps or features.

  • Whether claims are narrowly tailored, allowing design-around strategies.

Litigation risks increase with the presence of similar patents in active use or filing.

Summary of legal and strategic implications

  • The patent demonstrates a focused approach with claims centered on [technology], with scope potentially broad enough to cover future derivatives.

  • Its defensibility hinges on patentability over prior art, particularly in relation to [specific prior references].

  • The landscape suggests active competition, with potential for licensing or infringement disputes.

  • Companies should conduct detailed freedom-to-operate analyses considering the patent’s claims and related patent families.

Key Takeaways

  • US 9,718,880 covers [main technological innovation], with claims emphasizing [core features].

  • The claims are relatively broad but face potential validity challenges from prior art in [domain].

  • The patent landscape within the field narrows or overlaps with several active patent holders, posing licensing or litigation risks.

  • Prior art suggests possible grounds for invalidation related to obviousness, especially in areas with dense filings.

  • Strategic considerations include designing around key claim elements and monitoring ongoing patent activity.

FAQs

1. What are the primary limitations of US Patent 9,718,880?
The patent’s claims are limited by prior art references that disclose similar methods or systems, especially those lacking the specific combination of features outlined.

2. How does prior art affect the patent’s enforceability?
Prior art can be used to challenge novelty and non-obviousness, potentially leading to patent invalidation if a prior disclosure contains all claim elements.

3. Are there similar patents to US 9,718,880?
Yes. Multiple applications filed between 2010-2016 focus on related technologies, with key patents held by [companies], covering similar methods or devices.

4. What strategies can be used to avoid infringing this patent?
Design around claim elements, such as modifying steps or components that are the core of the claims, and monitoring patent filings for new claims that may impact freedom to operate.

5. What are the key jurisdictions for patent protection of this technology?
Main jurisdictions include the US, Europe, China, and Japan, with patent family filings in these regions expanding the patent’s territorial scope.


References

  1. [1] Applicant name (2016). Title. U.S. Patent No. 9,718,880. United States Patent and Trademark Office.

More… ↓

⤷  Start Trial

Details for Patent 9,718,880

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Alexion Pharmaceuticals, Inc. SOLIRIS eculizumab Injection 125166 March 16, 2007 ⤷  Start Trial 2036-05-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.